Cargando…

Safety profile of mRNA vaccines during first 6 months of the US COVID-19 vaccination programme reviewed

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9051809/ http://dx.doi.org/10.1007/s40278-022-13943-8

Ejemplares similares

Safety of mRNA COVID-19 vaccines during pregnancy
Publicado: (2022)

COVID-19 mRNA vaccine safety during the first 6 months of roll-out in the USA
por: Krantz, Matthew S, et al.
Publicado: (2022)

Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe
por: Rosenblum, Hannah G, et al.
Publicado: (2022)

Myocarditis rare after COVID-19 mRNA vaccination
Publicado: (2021)

COVID-19 mRNA vaccines: acute allergic reaction and anaphylaxis
Publicado: (2021)

Methotrexate adversely affects immunogenicity to COVID-19 mRNA vaccines
Publicado: (2021)

mRNA-based vs viral vector-based COVID-19 vaccines
Publicado: (2021)

No adverse effects found for prenatal exposure to mRNA COVID-19 vaccine
Publicado: (2022)

Low rate of myocarditis/pericarditis after COVID-19 mRNA vaccines
Publicado: (2022)

Fourth-dose boosters with COVID-19 mRNA vaccines well tolerated
Publicado: (2022)

Safety of mRNA-COVID-19 Vaccines in Patients With Thoracic Cancers
por: Spitaleri, G., et al.
Publicado: (2023)

mRNA COVID-19 vaccines safe in patients with previous COVID-19 infections
Publicado: (2022)

Cardiac risks higher after COVID-19 infection than mRNA vaccine
Publicado: (2022)

Safety of COVID-19 mRNA vaccination in children with chronic urticaria
por: Zhu, Catherine K., et al.
Publicado: (2023)

Younger males at greatest risk of myocarditis after mRNA-based COVID-19 vaccination
Publicado: (2022)

COVID-10 vaccine safety monitoring in US: no serious concerns
Publicado: (2021)

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
por: Thomas, Stephen J., et al.
Publicado: (2021)

Myocarditis following COVID-19 mRNA vaccination
por: Parmar, Kanak, et al.
Publicado: (2021)

mRNA COVID-19 vaccine safety in patients with previous immediate hypersensitivity to pegaspargase
por: Koo, Grace, et al.
Publicado: (2022)

Safety and immunogenicity of mRNA COVID‐19 vaccine in inpatients with muscular dystrophy
por: Saito, Tomoko, et al.
Publicado: (2022)

Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age
por: Anderson, Evan J., et al.
Publicado: (2022)

A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty® and COVID-19 mRNA Vaccine Moderna®
por: Speich, Benjamin, et al.
Publicado: (2021)

Hypereosinophilia after vaccination with the SARS-CoV-2 mRNA vaccines
por: Westreich, Aaron, et al.
Publicado: (2023)

Real-time analysis of a mass vaccination effort confirms the safety of FDA-authorized mRNA COVID-19 vaccines
por: McMurry, Reid, et al.
Publicado: (2021)

Safety of mRNA COVID-19 vaccines during pregnancy
por: Ellington, Sascha, et al.
Publicado: (2022)

Allergic symptoms after mRNA COVID-19 vaccination and risk of incomplete vaccination
por: Robinson, Lacey B., et al.
Publicado: (2021)

Immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients with primary brain tumors: a prospective cohort study
por: Massarweh, Amir, et al.
Publicado: (2022)

Comprehensive antibody profiling of mRNA vaccination in children
por: Bartsch, Yannic C, et al.
Publicado: (2022)

Acute Myocarditis Following Vaccination With the First Dose of the mRNA-1273 Vaccine
por: Olagunju, Abdulbaril, et al.
Publicado: (2022)

Safety, Effectiveness, and Immunogenicity 6 Months After BNT162B2 mRNA Vaccine in Frail Nursing Home Residents
por: Montejano-Hervás, Pablo, et al.
Publicado: (2022)

Safety of the BNT162b2 mRNA COVID-19 vaccine in patients with familial Mediterranean fever
por: Shechtman, Liran, et al.
Publicado: (2022)

Safety of BNT162b2 mRNA COVID-19 vaccine in patients with mast cell disorders
por: Rosman, Yossi, et al.
Publicado: (2021)

Safety and reactogenicity of second booster doses for mRNA vaccines
por: Wilder-Smith, Annelies, et al.
Publicado: (2023)

mRNA: Vaccine or Gene Therapy? The Safety Regulatory Issues
por: Banoun, Helene
Publicado: (2023)

mRNA as a Therapeutics: Understanding mRNA Vaccines
por: Oğuz, Ferdi, et al.
Publicado: (2022)

mRNA Vaccine Platform: mRNA Production and Delivery
por: Litvinova, V. R., et al.
Publicado: (2023)

Transcription Expression and Clinical Significance of Dishevelled-3 mRNA and δ-Catenin mRNA in Pleural Effusions from Patients with Lung Cancer
por: Li, Xiao-Yan, et al.
Publicado: (2012)

Dangers of mRNA vaccines
por: Ali, Tahoora, et al.
Publicado: (2021)

mRNA-Based Vaccines
por: Kowalzik, Frank, et al.
Publicado: (2021)

Advances in mRNA vaccines
por: Li, Mengyun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8lvbbjitfknrevj0spqa92h0un